查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997470

骨關節炎治療市場：按治療方法、給藥途徑、最終用戶和分銷管道分類的全球市場預測，2026-2032 年

Osteoarthritis Therapeutics Market by Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，骨關節炎治療市場價值將達到 55.5 億美元，到 2026 年將成長至 59.7 億美元，到 2032 年將達到 93.5 億美元，複合年成長率為 7.72%。

主要市場統計數據
基準年 2025 55.5億美元
預計年份：2026年 59.7億美元
預測年份 2032 93.5億美元
複合年成長率 (%) 7.72%

對當前骨關節炎治療範式和不斷發展的跨學科護理路徑進行簡明扼要且權威的概述，這些路徑影響著相關人員的決策。

骨關節炎仍然是最常見的退化性關節疾病之一，持續引發臨床關注和跨領域創新，旨在緩解疼痛、促進功能恢復並延緩或避免侵入性手術。近年來，治療方法日趨融合，涵蓋了從保守療法和輔助療法到先進的外科手術，這反映出以患者為中心、個體化的治療路徑正在轉變，力求在控制症狀和長期保護關節之間取得平衡。臨床醫生、保險公司和醫療保健機構越來越重視多學科管理，將藥物治療、物理治療、生活方式干涉和選擇性治療相結合，力求在最大限度減少副作用的同時最佳化治療效果。

這是重塑骨關節炎治療模式的關鍵轉折點，涵蓋多方面護理、生物製藥、數位化復健以及以價值主導的報銷體系的整合。

在骨關節炎治療領域，正在發生一些變革性的變化，這些變化正在重塑臨床實踐和商業策略。首先，治療方式明顯轉向多方面綜合治療，將針灸、按摩療法和營養補充劑等輔助療法與傳統藥物治療和針對性手法治療相結合。這種綜合模式認知到患者症狀的多樣性，並強調制定個人化的治療方案，從而有可能減少患者對全身性鎮痛藥的長期依賴。

本研究評估了整體年關稅變化和貿易政策調整將如何影響骨關節炎治療的供應鏈、採購經濟和商業化時間表。

近期關稅和貿易方面的動態可能會對骨關節炎藥物市場產生重大影響，因為這會影響進口到美國的醫療設備、植入和某些藥品原料的投入成本。對醫療設備和用於製造植入、關節鏡檢查設備以及某些注射藥物的原料徵收更高的關稅，可能會導致供應商的接收成本上升，促使製造商籌資策略、實現供應商多元化，並將製造地轉移到其他地區。因此，在洽談資本投資和植入合約時，醫院和診所可能會面臨壓力，需要爭取更高的價值、延長採購週期，或在條件允許的情況下優先選擇國內生產的替代品。

基於全面細分的洞察，將治療方法、給藥途徑、醫療保健服務環境和分銷管道與臨床和商業性進入因素聯繫起來。

一套精細的市場區隔框架揭示了每種治療類型、給藥途徑、最終用戶和分銷管道獨特的需求促進因素、治療路徑和商業性需求。根據治療類型，市場涵蓋了針灸、按摩療法和營養補充劑等輔助療法，以及從皮質類固醇注射、透明質酸注射到非類固醇消炎劑和鴉片類藥物等藥物療法。物理治療仍然是保守治療的核心，而外科治療則包括關節鏡、全關節重建和截骨術。特別是股骨和脛骨截骨術，需要不同的外科技術和植入選擇。每種治療路徑都有不同的證據閾值、患者接受度趨勢和報銷機制，這些因素都會影響其應用曲線和醫療服務提供者的獎勵。

將患者人口統計、報銷框架和臨床基礎設施與全球市場差異化的進入管道聯繫起來的區域戰略考量。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的醫療服務取得、應用和戰略重點，每個地區都擁有獨特的臨床基礎設施、報銷框架和患者群體特徵。在美洲，整合式醫療保健系統和私營部門的創新推動了微創手術和先進注射藥物的快速普及，同時，與保險公司的談判和基於價值的合約也日益影響著保險覆蓋範圍的決策和處方藥清單。同時，歐洲、中東和非洲地區的監管環境和採購模式則呈現多樣化的特徵。該地區既包括技術水平高、支付方成熟的市場，也包括那些因成本限制和醫療服務獲取差異而傾向於保守治療和可擴展康復方案的地區。

這種以創新為重點的競爭情報揭示了臨床證據、夥伴關係和服務模式如何重新定義骨關節炎治療的領導地位。

骨關節炎治療市場的競爭動態呈現出老牌企業與靈活敏捷的新興企業並存的局面，而差異化競爭日益依賴於臨床證據的強度、治療路徑的整合能力以及服務交付能力。領先的製藥和醫療設備公司持續投資於注射劑、植入材料和手術器材的漸進式創新改進，而新參與企業則專注於顛覆性方法，例如再生醫學、新型生物製藥和數位化復健平台。製造商、專科診所和數位化供應商之間的夥伴關係與協作正在加速商業性進程，並促成能夠將臨床結果與支付方價值目標相契合的綜合護理提案。

針對製造商、醫療保健提供者和支付方的具體策略措施，以加快實證實踐的採用，確保報銷，並加強供應鏈的韌性。

產業領導者應推動一系列切實可行且影響深遠的舉措，以應對當前骨關節炎治療的現狀並實現永續價值。首先，臨床開發應與支付方和醫療服務提供者關注的可操作終點保持一致，例如功能改善、療效持續以及對後續手術率的影響，同時將真實世界數據 (REW) 的收集納入核准後計劃，以支持報銷和分銷。其次，應制定與分銷通路和終端用戶需求相符的商業化策略。具體而言，這應包括確保醫院藥房能夠提供特製注射藥物，透過線上藥局為門診患者提供服務，以及與診所和復健中心合作建立多方面的護理路徑。

採用嚴謹的三角測量調查方法，結合臨床證據審查、相關人員訪談和通路分析，為策略建議奠定基礎。

本分析整合了基於三角測量法的調查方法，結合了結構化文獻綜述、專家訪談和分銷管道分析，確保了分析的深度和實用性。結構化文獻綜述涵蓋了同行評審的臨床研究、監管指南和專業學會建議，使治療主張與最新的臨床證據相符。對臨床醫生、採購經理和銷售主管的專家訪談，提供了對推廣障礙、處方趨勢和支付方談判動態的背景理解。同時，分銷管道分析檢驗了醫院藥局、線上藥局和零售藥局之間分銷的細微差異，反映了不同治療方法對物流和病患取得藥物的影響。

該摘要闡明了將臨床證據、已建立的分銷系統和營運彈性與骨關節炎治療的長期成功聯繫起來所面臨的戰略挑戰。

總之，骨關節炎的治療正處於臨床需求、技術創新和不斷發展的醫療服務模式的交會點。能夠將適應給藥途徑、醫療服務環境和分銷實際情況的實用商業策略與可靠的臨床證據相結合的相關人員，將最有能力為患者和支付方提供差異化的價值。輔助治療方法、標靶藥物治療、物理治療和外科手術技術的相互作用凸顯了建立能夠適應患者多樣性和當地醫療系統限制的綜合護理路徑的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的骨關節炎治療市場

  • 輔助療法
    • 針刺
    • 按摩療法
    • 營養補充品
  • 藥物治療
    • 皮質類固醇注射
    • 玻尿酸注射
    • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物
  • 物理治療
  • 外科手術
    • 關節鏡
    • 人工關節重建手術
    • 截骨術
      • 股骨截骨術
      • 脛骨截骨術

第9章：骨關節炎治療市場：依給藥途徑分類

  • 注射藥物
  • 口服
  • 外用
  • 經皮吸收

第10章：骨關節炎治療市場：依最終用戶分類

  • 診所
  • 醫院
  • 復健中心

第11章 骨關節炎治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 骨關節炎治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 骨關節炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 骨關節炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國骨關節炎治療藥物市場

第16章：中國骨關節炎治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Eli Lilly and Company
  • Endo International plc
  • Ferring BV
  • Fidia Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co.
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-DD6333AE50BA

The Osteoarthritis Therapeutics Market was valued at USD 5.55 billion in 2025 and is projected to grow to USD 5.97 billion in 2026, with a CAGR of 7.72%, reaching USD 9.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.55 billion
Estimated Year [2026] USD 5.97 billion
Forecast Year [2032] USD 9.35 billion
CAGR (%) 7.72%

A concise and authoritative overview of current osteoarthritis therapeutic paradigms and evolving multidisciplinary care pathways shaping stakeholder decision-making

Osteoarthritis remains one of the most prevalent degenerative joint disorders, driving sustained clinical attention and cross-sector innovation aimed at alleviating pain, restoring function, and delaying or avoiding invasive procedures. Recent years have seen a convergence of therapeutic approaches that span conservative complementary modalities through to advanced surgical interventions, reflecting a patient-centric shift toward personalized care pathways that balance symptom control with long-term joint preservation. Clinicians, payers, and providers increasingly emphasize multidisciplinary management, combining pharmacologic options with physical therapy, lifestyle interventions, and selective procedural therapies to optimize outcomes while minimizing adverse effects.

Concurrently, technology-enabled care models and digital therapeutics have expanded the toolkit available to clinicians and patients, enabling remote monitoring, adherence support, and rehabilitation at scale. These developments create new opportunities and complexities for stakeholders across the ecosystem, as they must reconcile clinical efficacy, reimbursement dynamics, and patient preferences. Importantly, regulatory scrutiny and safety considerations continue to shape the adoption of certain drug classes and intra-articular therapies, necessitating robust evidence generation and post-market surveillance.

As healthcare systems prioritize value-based care and longitudinal outcomes, strategic planning for osteoarthritis therapeutics requires nuanced understanding of treatment pathways, administration routes, and the providers who deliver care. This executive summary synthesizes current trends, structural shifts, and actionable insights that can inform R&D prioritization, portfolio management, and commercial strategies across pharmaceutical, medtech, and service delivery organizations.

Critical inflection points reshaping osteoarthritis treatment models including integration of multimodal care, biologics, digital rehabilitation, and value-driven reimbursement

The landscape of osteoarthritis therapeutics is undergoing several transformative shifts that are recalibrating clinical practice and commercial strategy. First, there is a clear reorientation toward multimodal care that integrates complementary therapies-such as acupuncture, massage therapy, and nutritional supplements-with traditional pharmacologic treatments and targeted procedural approaches. This integrated model acknowledges the heterogeneity of patient presentations and emphasizes individualized care plans that may reduce reliance on long-term systemic analgesics.

Second, advances in biologic and device-based interventions have elevated the role of localized therapies, including refined intra-articular injections and minimally invasive surgical techniques. These modalities aim to achieve symptom relief with lower systemic exposure, and their uptake is influenced by emerging clinical evidence, payer policies, and procedural capacity in outpatient and ambulatory settings. Third, digital health and tele-rehabilitation platforms are scaling access to supervised physical therapy and self-management programs, altering patient engagement and adherence dynamics and enabling providers to extend care beyond traditional brick-and-mortar encounters.

Fourth, payer and procurement strategies are increasingly focused on outcomes and cost-effectiveness, incentivizing care models that demonstrably reduce downstream resource utilization such as hospital readmissions or early joint replacement. Finally, cross-industry collaboration-spanning pharmaceuticals, medical device manufacturers, digital health vendors, and specialty clinics-is driving novel commercial partnerships and bundled care offerings. Together, these shifts demand adaptive strategies that align clinical evidence generation with novel delivery models and evolving reimbursement frameworks.

Assessing how tariff shifts and trade policy adjustments in 2025 can alter supply chains, procurement economics, and commercialization timelines across osteoarthritis therapeutics

Recent policy developments relating to tariffs and trade can exert meaningful influence on the osteoarthritis therapeutics landscape by affecting input costs for devices, implants, and certain pharmaceutical components imported into the United States. Increased duties on medical devices or raw materials used in manufacturing implants, arthroscopy equipment, and certain injectables can lead to higher landed costs for suppliers and may prompt manufacturers to reassess procurement strategies, supplier diversification, and regional manufacturing footprints. In turn, hospitals and clinics negotiating capital purchases and implant contracts may face pressure to extract greater value, extend procurement cycles, or prioritize domestically manufactured alternatives where available.

Moreover, tariffs can create short-term supply chain volatility that impacts inventory planning for hospital pharmacies, retail outlets, and online pharmacies that distribute osteoarthritis therapies. When suppliers anticipate cost headwinds, they often adjust pricing strategies, negotiate differently with distributors, or absorb margins selectively across portfolios, which can influence product availability and promotional investments. For innovators and smaller manufacturers, tariff-driven cost increases can heighten barriers to entry or slow commercialization timelines, particularly for capital-intensive device launches or complex biologic formulations that depend on specialized components.

In response, many stakeholders have accelerated supply chain resilience programs, including nearshoring, dual sourcing, and longer-term supplier agreements to mitigate exposure to tariff volatility. For health systems and group purchasing organizations, a strategic response includes scenario planning that integrates procurement flexibility, contract clauses addressing input-cost variability, and clinical substitution pathways that preserve care quality while managing cost. Ultimately, the cumulative impact of tariff changes in 2025 emphasizes the imperative for integrated commercial and supply chain strategies that protect access while sustaining innovation across therapeutics and devices.

Comprehensive segmentation-driven insights that map treatment modalities, administration routes, provider settings, and distribution channels to clinical and commercial adoption drivers

A nuanced segmentation framework illuminates distinct demand drivers, care pathways, and commercial imperatives across treatment type, route of administration, end-user, and distribution channel. Based on treatment type, the market comprises complementary therapies that include acupuncture, massage therapy, and nutritional supplements alongside drug therapy spanning corticosteroid injections, hyaluronic acid injections, non-steroidal anti-inflammatory drugs, and opioids; physical therapy modalities remain central to conservative management; and surgical solutions encompass arthroscopy, joint replacement, and osteotomy with femoral and tibial osteotomy subtypes that require distinct surgical expertise and implant considerations. Each of these treatment pathways has different evidence thresholds, patient acceptance dynamics, and reimbursement profiles, which in turn influence adoption curves and provider incentives.

Based on route of administration, therapies arrive via injectable, oral, topical, and transdermal pathways, with injectables attracting attention for their targeted delivery and potential for reduced systemic exposure, while oral and topical agents remain important for broad symptom management and ease of use. Based on end-user, clinics, hospitals, and rehabilitation centers each serve differentiated roles: clinics and outpatient centers emphasize access and conservative care delivery, hospitals provide surgical and acute interventions, and rehabilitation centers focus on intensive post-procedural recovery and functional restoration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies mediate how therapies reach patients, with each channel presenting unique considerations around inventory management, cold-chain logistics for certain injectables, patient counseling, and reimbursement coding.

Taken together, this segmentation underscores that product development, clinical trial design, and commercial planning must align with the practical realities of administration route, provider capabilities, and distribution pathways. Transitioning from clinical proof-of-concept to widespread adoption often requires tailored evidence packages, clinician education, and distribution agreements calibrated to the dominant channels serving target patient cohorts.

Regional strategic considerations tying patient demographics, reimbursement frameworks, and clinical infrastructure to differentiated adoption pathways across global markets

Regional dynamics shape access, adoption, and strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct clinical infrastructures, reimbursement frameworks, and patient demographics. In the Americas, integrated health systems and private sector innovation support rapid uptake of minimally invasive procedures and advanced injectables, while payer negotiation and value-based contracting increasingly determine coverage decisions and formulary placement. Conversely, Europe, Middle East & Africa exhibit heterogeneous regulatory landscapes and procurement models; this region combines markets with high procedural capacity and sophisticated payers alongside settings where cost containment and access gaps emphasize conservative care and scalable rehabilitation solutions.

Asia-Pacific presents a diverse mix of highly innovative markets with strong manufacturing capabilities and rapidly growing clinical volumes alongside emerging healthcare systems investing in surgical capacity and rehabilitation services. Across all regions, demographic shifts toward aging populations and rising prevalence of osteoarthritis amplify demand for effective, durable interventions and scalable care pathways. Regional reimbursement nuances influence the prioritization of certain therapies, with some payers favoring interventions demonstrating demonstrable reductions in downstream surgical interventions and others prioritizing short-term cost containment.

Given these regional contours, manufacturers and service providers must tailor market entry strategies, evidence generation plans, and commercial models to local regulatory expectations, distribution norms, and provider reimbursement incentives. Strategic partnerships with regional distributors, capacity-building programs for surgeons and rehabilitation teams, and differentiated pricing strategies are critical levers to bridge clinical innovation with sustainable access across diverse geographies.

Competitive and innovation-focused intelligence revealing how clinical evidence, partnerships, and service models are redefining leadership in osteoarthritis therapeutics

Competitive dynamics within osteoarthritis therapeutics reflect a blend of established incumbents and agile challengers, with differentiation increasingly driven by the strength of clinical evidence, pathway integration capabilities, and service-enablement. Leading pharmaceutical and device organizations continue to invest in incremental innovation-refinements to injectables, implant materials, and surgical instrumentation-while newer entrants emphasize disruptive approaches such as regenerative therapies, novel biologics, and digitally enabled rehabilitation platforms. Partnerships and alliances between manufacturers, specialty clinics, and digital vendors are accelerating commercial reach and enabling bundled care propositions that align clinical outcomes with payer value goals.

R&D pipelines emphasize improved safety profiles, targeted delivery, and longer durability of effect, with clinical programs designed to generate real-world evidence that supports favorable reimbursement decisions. For surgical device makers and implant suppliers, manufacturing scale, cost-efficient supply chains, and service models that support surgeon training and OR efficiency have become competitive differentiators. At the same time, distributors and pharmacy channels are optimizing logistics and patient services to support therapy adherence and home-based care models.

Strategic M&A activity and licensing deals have favored entities that can complement broader portfolios with specialty devices, high-value biologics, or digital infrastructure that enhances long-term patient monitoring. For commercial leaders, the priority is to align product positioning with provider workflows and payer benchmarks, invest in clinician education to accelerate uptake, and deploy health economics evidence that articulates the value proposition in terms of patient outcomes and resource utilization.

Actionable strategic measures for manufacturers, providers, and payers to accelerate evidence-informed adoption, secure reimbursement, and strengthen supply chain resilience

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate the current osteoarthritis therapeutics landscape and capture sustainable value. First, align clinical development with pragmatic endpoints that matter to payers and providers, including measures of functional improvement, durability of effect, and impact on downstream surgical rates, while integrating real-world evidence generation into post-approval plans to support reimbursement and uptake. Second, design commercialization strategies that match distribution channels and end-user needs: ensure hospital pharmacy readiness for specialty injectables, support online pharmacy patient services for outpatient therapies, and partner with clinics and rehabilitation centers to embed multimodal care pathways.

Third, invest in supply chain resilience and cost containment measures to mitigate exposure to tariff-related cost volatility and component shortages, including dual sourcing, regional manufacturing, and long-term supplier agreements. Fourth, develop bundled service offerings and clinician training programs that reduce barriers to adoption for novel surgical techniques and device platforms, and leverage digital rehabilitation and remote monitoring to extend patient engagement beyond the clinic. Fifth, cultivate payer engagement early to negotiate coverage pathways and value-based contracting that reflect long-term outcomes. Finally, prioritize cross-functional collaboration across R&D, commercial, regulatory, and supply chain teams to ensure coordinated launch execution and to adapt rapidly to evolving clinical evidence and reimbursement landscapes.

A rigorous, triangulated research methodology combining clinical evidence review, stakeholder interviews, and distribution channel analysis to underpin strategic recommendations

This analysis synthesizes insights derived from a triangulated research methodology combining structured literature review, expert interviews, and channel analysis to ensure both depth and practical relevance. The structured literature component encompassed peer-reviewed clinical studies, regulatory guidance, and specialty society recommendations to ground therapeutic claims in contemporary clinical evidence. Expert interviews with clinicians, procurement leaders, and commercial executives provided contextual understanding of adoption barriers, procedural trends, and payer negotiation dynamics, while channel analysis examined distribution nuances across hospital pharmacies, online pharmacies, and retail pharmacies to reflect the logistics and patient access implications of different therapies.

Where applicable, public regulatory filings and clinical trial registries informed assessment of pipeline priorities and safety considerations. The methodology emphasized cross-validation across data sources to enhance reliability and minimize bias, and findings were reviewed by practicing clinicians and industry experts to ensure practical applicability. Limitations of the research approach include heterogeneity in reporting standards across geographies and the evolving nature of tariff and trade policy, which necessitates ongoing monitoring. Nevertheless, the methodology provides a robust foundation for strategic decision-making by combining empirical clinical evidence, stakeholder perspectives, and operational channel insights.

Concluding synthesis that crystallizes strategic imperatives linking clinical evidence, distribution readiness, and operational resilience to long-term success in osteoarthritis care

In conclusion, osteoarthritis therapeutics occupy a dynamic intersection of clinical need, technological innovation, and evolving care delivery models. Stakeholders that successfully bridge robust clinical evidence with pragmatic commercial strategies-attuned to route of administration, provider settings, and distribution realities-will be best positioned to deliver differentiated value to patients and payers. The interplay of complementary therapies, targeted drug interventions, physical therapy, and surgical techniques underscores the necessity of integrated care pathways that are adaptable to patient heterogeneity and regional system constraints.

Supply chain resilience and strategic responses to tariff pressures will remain important operational considerations, particularly for devices and components with complex sourcing profiles. Competitive leadership will favor organizations that combine credible outcomes data, clinician engagement programs, and distribution capabilities across hospital, online, and retail channels. Ultimately, the most effective approaches are those that align product and service design with measurable improvements in patient function and quality of life while providing clear economic value to payers and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Therapeutics Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Acupuncture
    • 8.1.2. Massage Therapy
    • 8.1.3. Nutritional Supplements
  • 8.2. Drug Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.4. Opioids
  • 8.3. Physical Therapy
  • 8.4. Surgery
    • 8.4.1. Arthroscopy
    • 8.4.2. Joint Replacement
    • 8.4.3. Osteotomy
      • 8.4.3.1. Femoral Osteotomy
      • 8.4.3.2. Tibial Osteotomy

9. Osteoarthritis Therapeutics Market, by Route of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Osteoarthritis Therapeutics Market, by End-User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Rehabilitation Centers

11. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoarthritis Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Osteoarthritis Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Osteoarthritis Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Osteoarthritis Therapeutics Market

16. China Osteoarthritis Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bayer AG
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Cipla Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. Endo International plc
  • 17.13. Ferring B.V.
  • 17.14. Fidia Farmaceutici S.p.A
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Johnson & Johnson Services Inc.
  • 17.17. Merck & Co.
  • 17.18. Pfizer Inc.
  • 17.19. Sanofi S.A.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 201. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)